When will Aurobindo Pharma’s China plant start, CFO told the company’s complete plan
Santhanam Subramanian, Chief Financial Officer (CFO) of the country’s leading pharma company Aurobindo Pharma, made a big announcement on Monday. He expressed hope that the company’s unit in China will start production in the next quarter (October-December 2024). Additionally, the China-based plant is expected to begin full-scale production in the next fiscal year. The Hyderabad-based pharma company plans to start production in small quantities in the November-December period and hopes to scale it up in the January-March quarter next year.
What did the company’s CFO say about the Chinese plant?
Santhanam Subramanian said in a conversation with experts, “The China plant is expected to start from the third quarter of the financial year 2024-25 and production is expected to increase from the fourth quarter.” He said that this plant will be commissioned in the financial year 2025-26. Full production will begin.
Big increase in production expected from October this year
The company’s CFO said, “We are trying to do some filings for China as well as for the US. So all this will increase the revenue potential in China in the coming years. This year, we are looking at just a small volume and value Will see.” He said the company is also on the right track with regard to large-scale commercialization of Pen-G (penicillin). He said that the company is expecting a big increase in production from October this year.
Pen-G plant got approval under PLI scheme
The company’s Rs 2,400 crore Pen-G plant in Andhra Pradesh, which has been approved under the Production-Linked Incentive (PLI) Scheme to promote local manufacturing of critical key starting materials (KSM)/drug intermediates and active pharmaceutical ingredients (APIs) in the country Approval was given under. The annual production capacity of this plant will be around 15,000 tonnes.
